Press Releases Vaxxinity, Inc.

Stocks

VAXX

US92244V1044

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:52:29 09/07/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	-99.15%		-99.40%	-66.67%

20/06/24	Vaxxinity UB-312 Parkinson?s Trial Results Published in Nature Medicine	CI
12/05/24	Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P Global BMI Index	CI

Press Releases

20/06/24	Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine	GL
19/04/24	Vaxxinity Issues Shareholder Letter	GL
19/04/24	Vaxxinity Issues Shareholder Letter	AQ
19/04/24	Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock	GL
28/03/24	Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting	GL
27/03/24	Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates	GL
12/03/24	Vaxxinity : UB-312 Target Engagement - ADPD 2024	PU
07/03/24	Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024	GL
15/02/24	Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published	GL
13/02/24	Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	GL
13/02/24	Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	AQ
30/01/24	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	GL
30/01/24	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	AQ
18/01/24	Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	GL
18/01/24	Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	AQ
03/01/24	Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference	GL
13/11/23	Vaxxinity to Present at Upcoming November Medical and Investor Conferences	GL
13/11/23	Vaxxinity to Present at Upcoming November Medical and Investor Conferences	AQ
08/11/23	Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update	GL
08/11/23	Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update	AQ
11/09/23	Vaxxinity : H.C. Wainwright 25th Annual Global Investment Conference	PU
29/08/23	Vaxxinity to Present at Upcoming Investor Conferences in September	AQ
29/08/23	Vaxxinity to Present at Upcoming Investor Conferences in September	GL
10/08/23	Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease	GL
09/08/23	Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update	GL